Եվրոպական Միություն - ֆիններեն - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Եվրոպական Միություն - ֆիններեն - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipidimodifioivat aineet - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Եվրոպական Միություն - ֆիններեն - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Եվրոպական Միություն - ֆիններեն - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidien kuvantaminen - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Եվրոպական Միություն - ֆիններեն - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - eturauhasen kasvaimet, kastraatio-resistentin - terapeuttiset radiofarmaseuttiset valmisteet - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Ֆինլանդիա - ֆիններեն - Fimea (Suomen lääkevirasto)

polpharma s.a. - risperidonum - tabletti, kalvopäällysteinen - 0.5 mg - risperidoni

Ֆինլանդիա - ֆիններեն - Fimea (Suomen lääkevirasto)

polpharma s.a. - risperidonum - tabletti, kalvopäällysteinen - 1 mg - risperidoni

Ֆինլանդիա - ֆիններեն - Fimea (Suomen lääkevirasto)

polpharma s.a. - risperidonum - tabletti, kalvopäällysteinen - 2 mg - risperidoni

Ֆինլանդիա - ֆիններեն - Fimea (Suomen lääkevirasto)

polpharma s.a. - risperidonum - tabletti, kalvopäällysteinen - 3 mg - risperidoni

Ֆինլանդիա - ֆիններեն - Fimea (Suomen lääkevirasto)

polpharma s.a. - risperidonum - tabletti, kalvopäällysteinen - 4 mg - risperidoni